Independent
Tenure on this board
0.4 yrs
Also a director at
Matinas Biopharma Holdings Inc (MTNB)
Meeting calendar
INDP · Special meeting · Thursday, February 26, 2026
Indaptus Therapeutics Inc
2 nominees · 8 ballot items.
Election of two directors; approval of issuance/conversion of Preferred Stock (change of control, related party, and issuance approvals); approval of reverse stock split (1-for-2 to 1-for-199); increase authorized common stock; permit stockholder written consent; and adjournment if necessary.
Market cap
$287M
1Y TSR
-71.8%
Board grade
C-
Record date
Jan 21, 2026
Filing
DEF 14A
Meeting concluded · Feb 26, 2026
Follow how the vote landed and what changed on Indaptus Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot8
- 1
Election of Directors
ManagementBoard: FORElect Jerome Jabbour as Class I director and Matthew McMurdo as Class III director for terms expiring 2028 and 2027, respectively.
- 2
Change of Control Proposal
ManagementBoard: FORApprove issuance of common stock upon conversion of Series AA and Series AAA Preferred Stock (collectively, Preferred Stock) in accordance with Nasdaq Listing Rule 5635(b), which would result in significant ownership by the investor.
- 3
Related Party Proposal
ManagementBoard: FORApprove issuance of common stock upon conversion of Preferred Stock to David E. Lazar (Chairman and Co-CEO) under Nasdaq Listing Rule 5635(c) due to potential equity compensation treatment.
- 4
Issuance Proposal
ManagementBoard: FORApprove issuance of common stock upon conversion of Preferred Stock under Nasdaq Listing Rule 5635(d) because conversion would equal 19.99% or more of outstanding common stock at a price below Nasdaq Minimum Price.
- 5
Reverse Stock Split Proposal
ManagementBoard: FORApprove amendment to Charter to permit Board to effect up to two reverse stock splits at an aggregate ratio of 1-for-2 to 1-for-199, with the Board selecting the ratio within the range to increase per-share price.
- 6
Authorized Stock Increase Proposal
ManagementBoard: FORApprove amendment to Charter to increase authorized common stock from 200,000,000 to up to 1,000,000,000 shares.
- 7
Written Consent Proposal
ManagementBoard: FORApprove amendment to Charter to allow stockholder action by written consent (unanimous consent provision), subject to rights of preferred holders.
- 8
Adjournment Proposal
ManagementBoard: FORAuthorize proxy holders to adjourn or postpone the Special Meeting to solicit additional proxies if needed to establish quorum or approve proposals 1–7.
Director elections
Nominees on the ballot2
Not independent
Tenure on this board
0.1 yrs
Ownership
Latest 13F quarterTop institutional holders7
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 0.0% | 39,018 | $71K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 0.0% | 26,292 | $48K |
| 3 | MORGAN STANLEY | 0.0% | 2,697 | $5K |
| 4 | Tower Research Capital LLC (TRC | 0.0% | 1,890 | $3K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.0% | 715 | $1K |
| 6 | SBI Securities Co., Ltd. | 0.0% | 17 | $31 |
| 7 | CWM, LLC | 0.0% | 2 | $4 |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Indaptus Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Reference
Frequently asked questions
- When is the Indaptus Therapeutics Inc 2026 special meeting?
- Indaptus Therapeutics Inc (INDP) holds its 2026 special shareholder meeting on Thursday, February 26, 2026.
- What is the record date for the Indaptus Therapeutics Inc 2026 meeting?
- The record date for the Indaptus Therapeutics Inc 2026 meeting is Wednesday, January 21, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Indaptus Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Indaptus Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Indaptus Therapeutics Inc 2026 meeting?
- Shareholders will vote on 8 proposals at the Indaptus Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.